Targeting both Notch and ErbB-2 signalling pathways is required for prevention of ErbB-2-positive breast tumour recurrence

BACKGROUND: We reported that Notch-1, a potent breast oncogene, is activated in response to trastuzumab and contributes to trastuzumab resistance in vitro. We sought to determine the preclinical benefit of combining a Notch inhibitor (γ-secretase inhibitor (GSI)) and trastuzumab in both trastuzumab-...

Descripción completa

Detalles Bibliográficos
Autores principales: Pandya, K, Meeke, K, Clementz, A G, Rogowski, A, Roberts, J, Miele, L, Albain, K S, Osipo, C
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Nature Publishing Group 2011
Materias:
Translational Therapeutics
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3171020/
https://www.ncbi.nlm.nih.gov/pubmed/21847123
http://dx.doi.org/10.1038/bjc.2011.321

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3171020/
https://www.ncbi.nlm.nih.gov/pubmed/21847123
http://dx.doi.org/10.1038/bjc.2011.321

Ejemplares similares